Correspondence 0001641172-25-002810 from Insight Molecular Diagnostics Inc. (IMDX)

Insight Molecular Diagnostics Inc.
Date: April 4, 2025 · CIK: 0001642380 · Accession: 0001641172-25-002810

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-286251

Date

April 4, 2025

Author

President

Form

CORRESP

Company

Insight Molecular Diagnostics Inc.

Letter

Oncocyte Corporation

Cushing

Irvine, California 92618

April 4, 2025

VIA EDGAR

Division of Corporation Finance

Office of Life Sciences

U.S. Securities and Exchange Commission

Washington, D.C. 20549

Attention: Alan Campbell

Re: Oncocyte Corporation Registration Statement on Form S-1 Originally filed on March 28, 2025 File No. 333-286251 (the “ Registration Statement ”) Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “ Commission ”) under the Securities Act of 1933, as amended, Oncocyte Corporation (the “ Company ”) hereby respectfully requests acceleration of the effective date of the Registration Statement, so that it may become effective at 4:00 p.m., Eastern Time, on April 7, 2025, or as soon thereafter as practicable.

Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Jayun Koo, Esq. at (212) 835-4823.

Very
truly yours,
Oncocyte
Corporation

Show Raw Text

CORRESP
 1
 filename1.htm

 Oncocyte
Corporation

 15
Cushing

 Irvine,
California 92618

 April
4, 2025

 VIA
EDGAR

 Division
of Corporation Finance

 Office
of Life Sciences

 U.S.
Securities and Exchange Commission

 Washington,
D.C. 20549

 Attention:
Alan Campbell

 Re:
 Oncocyte
 Corporation
 Registration
 Statement on Form S-1
 Originally
 filed on March 28, 2025
 File
 No. 333-286251 (the “ Registration Statement ”)
 Request
 for Acceleration

 Ladies
and Gentlemen:

 Pursuant
to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “ Commission ”) under
the Securities Act of 1933, as amended, Oncocyte Corporation (the “ Company ”) hereby respectfully requests acceleration
of the effective date of the Registration Statement, so that it may become effective at 4:00 p.m., Eastern Time, on April 7, 2025, or
as soon thereafter as practicable.

 Should
any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes
and Boone, LLP, attention: Jayun Koo, Esq. at (212) 835-4823.

 Very
 truly yours,

 Oncocyte
 Corporation

 By:
 /s/
 Josh Riggs

 Josh
 Riggs

 President
 and Chief Executive Officer

 cc:
Jayun Koo, Esq., Haynes and Boone, LLP

SecProbe.io